Delving into the Latest Updates on Alcon Laboratories UK Ltd. with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

CA2 x β-adrenoceptors	1

关联

1

项与 Alcon Laboratories UK Ltd. 相关的药物

Brinzolamide/Timolol Maleate

布林佐胺噻吗洛尔

靶点

CA2 x β-adrenoceptors

作用机制

CA2抑制剂 [+1]

在研机构

Novartis Pharma AG [+2]

原研机构

Alcon AG

在研适应症

青光眼 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2008-11-25

1

项与 Alcon Laboratories UK Ltd. 相关的临床试验

CTRI/2023/11/060210 / Not yet recruiting临床4期

Clinical evaluation of retinal perfusion when performing cataract surgery with low vs high preset IOP in eyes with diabetic retinopathy - NIL

开始日期2023-12-02

申办/合作机构

Alcon Laboratories UK Ltd.

100 项与 Alcon Laboratories UK Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Alcon Laboratories UK Ltd. 相关的专利（医药）

登录后查看更多信息

5

项与 Alcon Laboratories UK Ltd. 相关的文献（医药）

2006-09-01·Current Medical Research and Opinion4区 · 医学

Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK

4区 · 医学

Article

作者: Guest, Julian F. ; Smith, Andrew F. ; Clegg, John P.

OBJECTIVEThis study estimated the health economic impact of olopatadine (Opatanol) compared to branded cromoglycate (Opticrom) and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis (SAC) in the UK.DESIGN AND SETTINGThis was a modelling study performed from the perspective of the UK's National Health Service (NHS).METHODSA decision model was constructed depicting the management of SAC sufferers who are 4 years of age or above over a typical allergy season of 4 months and considers the decision by a GP to initially treat a patient with olopatadine, branded or generic cromoglycate. The analysis assumed both drugs to be equally effective. Consequently, a cost-minimisation analysis was performed to identify the least costly alternative.MAIN OUTCOME MEASURES AND RESULTSStarting treatment with olopatadine is expected to lead to a healthcare cost of 92 pounds sterling (95% CI: 46 pounds sterling; 150 pounds sterling) over 4 months compared to 109 pounds sterling (95% CI: 65 pounds sterling; 166 pounds sterling) with branded cromoglycate and 95 pounds sterling (95% CI: 51 pounds sterling; 152 pounds sterling) with generic cromoglycate, resulting in a 16% and 3% reduction in healthcare costs respectively over 4 months of treatment. This cost-difference is primarily due to fewer GP visits among olopatadine-treated patients.CONCLUSIONUse of olopatadine instead of branded or generic cromoglycate affords an economic benefit to the NHS. Hence, within the limitations of the model, olopatadine is the preferred first-line treatment for use in SAC sufferers, since it is expected to lead to fewer GP visits, thereby releasing healthcare resources for alternative use.

2002-05-24·Modern Pharmaceutics, Fourth Edition

European Aspects of the Regulation of Drug Products with Particular Reference to Development Pharmaceutics

作者: Matthews, Brian R.

A review and discussion.The regulatory requirements relating to data on development pharmaceutics and process validation are discussed.The discussion is limited to Marketing Authorization Applications for the European Economic Area and many central and eastern European countries.Documents used to prepare this article are listed.

2000-07-28·Drugs and the Pharmaceutical Sciences

Regulatory Aspects of Stability Testing in Europe

作者: Matthews, Brian R.

A review with 1 referencesReasons for drug stability studies, pharmaceutical expert reports, postmarketing changes, drug-device combinations, impurities in new active substances, stability testing of new drugs and products, etc., are discussed.

100 项与 Alcon Laboratories UK Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Alcon Laboratories UK Ltd. 相关的转化医学

登录后查看更多信息